SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001564590-21-021350
Filing Date
2021-04-28
Accepted
2021-04-28 16:10:42
Documents
14
Period of Report
2021-04-28
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K vktx-8k_20210428.htm   iXBRL 8-K 35465
2 EX-99.1 vktx-ex991_6.htm EX-99.1 226075
3 GRAPHIC gahp14bry4gf000001.jpg GRAPHIC 13142
  Complete submission text file 0001564590-21-021350.txt   424121

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA vktx-20210428.xsd EX-101.SCH 5816
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE vktx-20210428_lab.xml EX-101.LAB 19478
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vktx-20210428_pre.xml EX-101.PRE 11660
7 EXTRACTED XBRL INSTANCE DOCUMENT vktx-8k_20210428_htm.xml XML 3562
Mailing Address 12340 EL CAMINO REAL, SUITE 250 SAN DIEGO CA 92130
Business Address 12340 EL CAMINO REAL, SUITE 250 SAN DIEGO CA 92130 858-704-4660
Viking Therapeutics, Inc. (Filer) CIK: 0001607678 (see all company filings)

IRS No.: 461073877 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37355 | Film No.: 21864338
SIC: 2834 Pharmaceutical Preparations